JP Morgan Upgrades Solid Biosciences to Neutral

JP Morgan analyst Anupam Rama upgrades Solid Biosciences (NASDAQ:SLDB) from Underweight to Neutral.

JP Morgan analyst Anupam Rama upgrades Solid Biosciences (NASDAQ:SLDB) from Underweight to Neutral.

Total
0
Shares
Related Posts
Read More

AstraZeneca-Merck’s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October’s Key PDUFA Catalysts Biotech Investors Must Know

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.

ALNY